Navamedic — Earnings Release 2021

Dec 23, 2021

Navamedic ASA: Trading Update

Navamedic ASA: Trading Update

Oslo, 23 December 2021 - Navamedic ASA (OSE: NAVA) today announces a trading

update based on updated revenue growth expectation for the full-year 2021 of

around 30%, compared to the previously communicated annual growth target of 20%.

The revenue growth is driven by strong performance in Q4 with a particularly

strong December month.

Reference is made to Navamedic's communicated target of 20% annual growth for

2021. As the company's preliminary financial results for Q4, and hence the full

year 2021, represent a noticeable improvement compared to the communicated

target for 2021, the company has decided to provide a trading update based on an

updated revenue growth expectation for the full-year 2021 of around 30%.

"Our portfolio of specialty pharma and consumer health products continues to

grow with particularly strong performance for the obesity product Mysimba. The

growth in the fourth quarter and December in particular has been stronger than

expected. We are pleased to see this development, and to provide an updated

revenue growth expectation for the full year 2021 compared to 2020 of around

30%," says Kathrine Gamborg Andreassen, Chief Executive Officer of Navamedic

ASA.

Navamedic wants to reiterate that that the books for Q4 2021 are not closed,

that the revenue growth in 2021 thus at this stage is an estimate and that the

final numbers will be communicated on Navamedic's presentation of the Q4 numbers

on February 17, 2022.

Going into 2022, Navamedic maintains its annual growth target of 20% and its mid

-term ambition of building a NOK 500 million company through organic growth with

strong gross margins and underlying profitability.

This information is considered to be inside information pursuant to the EU

Market Abuse Regulation and is subject to the disclosure requirements pursuant

to Section 5-12 the Norwegian Securities Trading Act. The information was

submitted for publication, through Newsweb by Lars Hjarrand at 13:34 hrs CET on

23 December 2021.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47917 62842

E-mail: lars.hjarrand@navamedic.com

About

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality

products, delivered to hospitals and through pharmacies, meeting the specific

needs of patients and consumers by leveraging its highly scalable market access

platform, leading category competence and local knowledge. Navamedic is present

in all the Nordic countries, the Baltics and Benelux, with sales representation

in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on

the Oslo Stock Exchange (ticker: NAVA). For more information, please

visitwww.navamedic.com